Dr. Reddy’s Laboratories recently announced the U.S. market launch of Lenalidomide Capsules, a therapeutic equivalent generic version of Revlimid (lenalidomide) Capsules approved by the U.S. FDA. With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths. “We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusiv...